The high price target for XFOR is $21.00 and the low price target for XFOR is $15.00. The chart below shows how a company's share price and consensus price target have changed over time. The consensus rating is ‘Buy’. Please log in to your account or sign up in order to add this asset to your watchlist. While it has been gaining momentum since that abrupt descent, the company is cognizant that better results are needed quickly. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy.". Get the latest X4 Pharmaceuticals, Inc. XFOR detailed stock quotes, stock data, … 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 The technical analysis gauge below displays real-time ratings for the timeframes you select. The range between the high target price and low target price is between 23 and 14 calculating the mean target price we have 18.75. View which stocks are hot on social media with MarketBeat's trending stocks report. View insider buying and selling activity for X4 Pharmaceuticals or or view top insider-buying stocks. To see all exchange delays and terms of use please see disclaimer. X4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts. There are currently 7 buy ratings for the stock. Our recommended stop-loss: We hold an negative evaluation for this stock. Learn everything you need to know about successful options trading with this three-part video course. X4 Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021. Vote “Outperform” if you believe XFOR will outperform the S&P 500 over the long term. X4 Pharmaceuticals (XFOR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes. Learn about financial terms, types of investments, trading strategies and more. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). All rights reserved. See what's happening in the market right now with MarketBeat's real-time news feed. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Get daily stock ideas top-performing Wall Street analysts. Since then, XFOR shares have increased by 14.9% and is now trading at $9.86. Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($2.79) to ($2.50) per share. The company can be reached via phone at 857-529-8300 or via email at [email protected]. Shares of XFOR can be purchased through any online brokerage account. XFOR stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, and Zacks Investment Management. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. View our full suite of financial calendars and market data tables, all for free. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. X4 Pharmaceuticals has received 56 “outperform” votes. Looking to buy X4 Pharmaceuticals Inc stock? High institutional ownership can be a signal of strong market trust in this company. X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Their forecasts range from $15.00 to $21.00. -- (BUSINESS WIRE)--Apr. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The lighter blue line represents the stock's consensus price target. X4 Pharmaceuticals with ticker code (XFOR) now have 8 analysts in total covering the stock. See X4 Pharmaceuticals Inc real time stock price, historical quotes and price charts. The dark blue line represents the company's actual price. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Fundamental company data provided by Zacks Investment Research. A high-level overview of X4 Pharmaceuticals, Inc. (XFOR) stock. The consensus among Wall Street equities research analysts is that investors should "buy" X4 Pharmaceuticals stock. Some companies that are related to X4 Pharmaceuticals include Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Agenus (AGEN), Precision BioSciences (DTIL), DBV Technologies (DBVT), MeiraGTx (MGTX), Compugen (CGEN), Curis (CRIS), Oyster Point Pharma (OYST), Gritstone Oncology (GRTS), Jounce Therapeutics (JNCE), Freeline Therapeutics (FRLN), Harpoon Therapeutics (HARP), Fusion Pharmaceuticals (FUSN) and AVROBIO (AVRO). © American Consumer News, LLC dba MarketBeat® 2010-2021. Receive a free world-class investing education from MarketBeat. Find real-time XFOR - X4 Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Every day, we strive to advance our pipeline of innovative medicines to treat rare diseases. X4 Pharmaceuticals has a P/B Ratio of 0.95. The stock dropped 21% from its high of … Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Export data to Excel for your own analysis. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Identify stocks that meet your criteria using seven unique stock screeners. Specifically, they have bought $0.00 in company stock and sold $92,688.00 in company stock. BioMarin Pharmaceutical (NASDAQ:BMRN) has not escaped the market sell-off caused by the COVID-19 pandemic. Should I buy Takeda Pharmaceutical Co. (TAK)? View insider buying and selling activity for X4 Pharmaceuticals or view top insider-selling stocks. According to analysts’ consensus price target of $21.43, X4 Pharmaceuticals has … View which stocks have been most impacted by COVID-19. 0. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Is it a good time to buy X4 Pharmaceuticals stock? and Translational Research, Start Your Risk-Free Trial Subscription Here, Anheuser-Busch Inbev Stock is a Must Own Re-Opening Play, Casey's General Stores is Still a Good Buy, FlexShopper Stock: Small Price, Big Upside, Why Visa (NYSE:V) Stock Deserves More Credit, Thor Industries (NYSE:THO) Deserves A Spot In Your Pantheon Of Stocks, Chipotle Continues To Impress Wall Street, ABM Industries Incorporated: High-Demand Service For Reopening Businesses, Texas Roadhouse Looks Like a Post-Pandemic Winner, Purple Innovation Attempts Rebound After Earnings Dive, ChargePoint Stock is a Speculative EV Play Only for the Nimble and Risk-Tolerant, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update, X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on, X4 Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host a Conference Call and Webcast on March 4, 2021, X4 Pharmaceuticals to Participate at the Virtual B. Riley Oncology Institutional Investor Conference, X4 Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect Conference, X4 Pharmaceuticals Appoints Diego Cadavid, M.D., as Chief Medical Officer, X4 Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Mavorixafor for the Treatment of WHIM Syndrome, X4 Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference, X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q3 2020 Results - Earnings Call Transcript, X4 Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update, X4 Pharmaceuticals Appoints Art Taveras, Ph.D., as Chief Scientific Officer, Kaskela Law LLC Announces Stockholder Investigation of X4 Pharmaceuticals, Inc. - XFOR, X4 Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020, X4 Pharma's lead asset Fast Track'd for rare congenital immunodeficiency disorder, Three Attractive Health Care Growth Stocks, X4 Pharmaceuticals to Participate in Three September Virtual Investor Conferences, X4 Pharmaceuticals Announces Publication of Mavorixafor Phase 2 Clinical Data for Treatment of WHIM Syndrome in ‘Blood’ - the Official Journal of the American Society of Hematology, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Looking for new stock ideas? The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.87) by $0.04. 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. Wall Street analysts have given X4 Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Vote “Underperform” if you believe XFOR will underperform the S&P 500 over the long term. Stay up to date with X4 Pharmaceuticals Inc stock news. MarketBeat just released five new trading ideas, but X4 Pharmaceuticals wasn't one of them. View X4 Pharmaceuticals' earnings history. The stock's lowest day price was 7.25.X4 Pharmaceuticals has 52 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 30 trading days. View analyst ratings for X4 Pharmaceuticals or view top-rated stocks. Invest in X4 Pharmaceuticals Inc stock and others with any dollar amount. Export data to Excel for your own analysis. Find the latest X4 Pharmaceuticals, Inc. (XFOR) stock quote, history, news and other vital information to help you with your stock trading and investing. 7 Wall Street analysts have issued ratings and price targets for X4 Pharmaceuticals in the last 12 months. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. X4 Pharmaceuticals' management team includes the following people: Director of Corp. Communications & Investor Relations, Sr. VP of Clinical Devel. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Looking for new stock ideas? Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate. X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Fundamental company data provided by Zacks Investment Research. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Learn more. X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its quarterly earnings data on Thursday, March, 4th. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Buy and Hold Grade: C. The stock’s proximity to its 52-week high is a key factor that our Buy and Hold Grade considers, and ARNA lost points when its stock went kerplunk in November after the Q3 results. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. X4 Pharmaceuticals has received 54.90% “outperform” votes from our community. View our full suite of financial calendars and market data tables, all for free. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. X4 Pharmaceuticals' stock is owned by a variety of retail and institutional investors. X4 Pharmaceuticals Inc. stock price up 3.49% on Friday (Updated on March 05, 2021) Buy or Hold candidate since 2021-01-05 Gain 38.69% PDF The X4 Pharmaceuticals Inc. stock price gained 3.49% on the last trading day (Friday, 5th Mar 2021), rising from $9.18 to $9.50. Our grit drives solutions for patients. View analysts' price targets for X4 Pharmaceuticals or view top-rated stocks among Wall Street analysts. X4 Pharmaceuticals, Inc. Common Stock (XFOR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Compare Top Brokerages Here. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Learn more. The official website for X4 Pharmaceuticals is www.x4pharma.com. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. In the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX). MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. XFOR stock was bought by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, BlackRock Inc., JPMorgan Chase & Co., Minot Wealth Management LLC, Wells Fargo & Company MN, Barclays PLC, Renaissance Technologies LLC, and Squarepoint Ops LLC. By targeting the CXCR4 pathway, our novel medicines are designed to restore healthy immunity in patients with rare diseases. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. 12, 2019-- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering of 5,670,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 2,130,000 shares of common stock… Want to see which stocks are moving? Buy X4 Pharmaceuticals Inc stock (XFOR). CAMBRIDGE, Mass. Learn more. © American Consumer News, LLC dba MarketBeat® 2010-2021. MarketBeat's community ratings are surveys of what our community members think about X4 Pharmaceuticals and other stocks. During the day the stock fluctuated 7.99% from a day low at $8.82 to a day high of $9.53. Want to see which stocks are moving? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. X4 Pharmaceuticals has received a consensus rating of Buy. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. X4 Pharmaceuticals, Inc. (XFOR) is making a move up in the market today. X4 Pharmaceuticals (XFOR) Gets a Buy Rating from Brookline Capital Markets Jan. 4, 2021 at 7:35 a.m.